Magle Group has signed an agreement with Rifa Pharma for the distribution of SmartPAN and SmartGEL medical technologies in India.
The move marks a step forward in the group’s global expansion and aims to deliver surgical and wound-care technologies to healthcare professionals.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SmartPAN is used to detect leakage of pancreatic fluid during open or minimally invasive surgical procedures. It is approved for commercialisation in Europe, carrying the CE mark.
The SmartGEL hydrogel wound dressing is designed for managing dry to moderately exuding partial and full-thickness wounds.
The agreement grants Rifa Pharma exclusive rights to commercialise these technologies.
It specifies each party’s roles in distribution, regulatory support, and market development, and is set up as a long-term collaboration aimed at supporting ongoing market entry and growth.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRifa Pharma CEO Dr Sanjay Loomba said: “We are delighted to partner with Magle Group and to bring SmartPAN and SmartGEL to surgeons and clinicians across India.
“These technologies address real clinical needs and align with our mission to provide safe, effective, and innovative solutions that improve patient outcomes. We look forward to building a strong and enduring collaboration.”
The commercial preparations and regulatory clearance processes of the partnership are currently underway.
Magle Group’s chief marketing and innovation officer Helena Ossmer Thedius said: “India is a strategically important market for Magle Group, and partnering with Rifa Pharma enables us to reach clinicians and patients at scale with trusted and experienced local support.
“Rifa Pharma’s commitment to quality and their deep local expertise make them an ideal partner as we continue to expand our international footprint. We are excited about the potential of this collaboration.”
Magle Group operates through three divisions, notably Magle Chemoswed, which functions as a contract development and manufacturing organisation (CDMO); Magle PharmaCept, which handles sales and marketing for the group’s medical technology products; and Magle Biopolymers, a specialised manufacturing division focused on Dextran technology.
